Relation between depression, some laboratory parameters, and quality of life in hemodialysis patients

Renal Failure

Volumn 27, Issue 6, 2005, Pages 695-699

  Dogan, Ekrem ^a,c   Erkoc, Reha ^a   Eryonucu, Buket ^b   Sayarlioglu, Hayriye ^b   Agargun, Mehmet ^b  

^a Medical Faculty   (Turkey)

^b YUZUNCU YIL UNIVERSITY   (Turkey)

^c KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

Author keywords

Depression; Hamilton anxiety; Hemodialysis; Laboratory parameters; Quality of life

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; HEMOGLOBIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DIABETES MELLITUS; FEMALE; GLOMERULONEPHRITIS; HAMILTON SCALE; HEALTH STATUS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HOSPITAL LABORATORY; HUMAN; KIDNEY FAILURE; MALE; PATIENT CARE; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; RISK ASSESSMENT; SHORT FORM 36;

ADAPTATION, PHYSIOLOGICAL; ADAPTATION, PSYCHOLOGICAL; ADULT; BLOOD CHEMICAL ANALYSIS; COHORT STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROBABILITY; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RENAL DIALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 28644451406     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220500242728     Document Type: Article

References (25)

1. Spilker B. Quality of Life Assessment in Clinical Trial. New York, NY: Raven, 1990.
2. Lee SY, Lee HJ, Kim YK, et al. Neurocognitive function and quality of life in relation to hematocrit levels in chronic hemodialysis patients. J Psychosom. Res. 2004;57(1):5-10.
3. Lew SQ, Piraino B. Quality of life and psychological issues in peritoneal dialysis patients. Semin Dial. 2005;18(2):119-123.
4. Wuerth D, Finkelstein SH, Finkelstein FO. The identification and treatment of depression in patients maintained on dialysis. Semin Dial. 2005;18(2):142-146.
5. Kimmel PL, Peterson RA. Depression in end-stage renal disease patients treated with hemodialysis: tools, correlates, outcomes, and needs. Semin Dial. 2005;18(2):91-97.
6. NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation. Am J Kidney Dis. 1997;30:S15-S136.
7. Demirsoy AD. The MOS SF-36 Health Survey: a validation study with a Turkish Sample. In: Unpublished master's thesis. Istanbul: Department of Psychology, Bogaziçi University, 1999, [in Turkish].
8. Yazici MK, Demir B, Tanriverdi N, Karaagaoglu E, Yolaç P. Validity and inter-rater reliability of Hamilton Anxiety Rating Scale [Turkish]. Turk Psikiyat Derg. 1998;9:114-117.
9. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE Jr. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7:763-773.
10. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of hemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003;18:353-361.
11. Koo JR, Yoon JW, Kim SG, et al. Association of depression with malnutrition in chronic hemodialysis patients. Am J Kidney Dis. 2003;41(5):1037-1042.
12. Koo JR, Yoon JY, Joo MH, et al. Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. Am J Med Sci. 2005;329(1):1-5.
13. Lundin AP, Akerman MJ, Chesler RM, et al. Exercise in hemodialysis patients after treatment with recombinant human erythropoietin. Nephron. 1991;58:315-319.
14. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol. 1991;35:280-287.
15. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996;11:1277-1285.
16. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 2000;35:250-256.
17. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol. 2000;11:335-342.
18. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis. 1999;33:1122-1130.
19. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;25:74-80.
20. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
21. Maes M, Song C, Lin A, et al. Immune and clinical correlates of psychological stress-induced production of interferon-γ and interleukin-10 in humans. In: Plotnikoff N, Murgo A, Faith R, Good R, eds. Cytokines: Stress and Immunity. Boca Raton, FL: CRC Press, 1999:39-47.
22. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol. 2002;90:1279-1283.
23. Ladwig KH, Marten-Mittag B, Lowel H, Doring A, Koenig W. Influence of depressive mood on the association of CRP and obesity in 3205 middle aged healthy men. Brain Behav Immun. 2003;17(4):268-275.
24. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2004;164(9):1010-1014.
25. Hung CY, Chen YA, Chou CC, Yang CS. Nutritional and inflammatory markers in the prediction of mortality in Chinese hemodialysis patients. Nephron Clin Pract. 2005;100(1):c20-c26 [Epub ahead of print].